Table 5. Correlation between the clinicopathologic characteristics and HDAC3 expression (n = 84).

Clinicopathological parameters	No.of patients	Nuclear HDAC3 (n, %)			Cytoplasmic HDAC3 (n, %)
		Low	High	P-value	Low	High	P-value
Cases	84	38 (45.2)	46 (54.8)		38 (45.2)	46 (54.8)
Age (years)
≤ 60	39	19 (48.7)	20 (51.3)	0.551a	18 (46.2)	21 (53.8)	0.875a
> 60	45	19 (42.2)	26 (57.8)		20 (44.4)	25 (55.6)
Gender
Male	51	20 (39.2)	31 (60.8)	0.168a	25 (49.0)	26 (51.0)	0.387a
Female	33	18 (54.5)	15 (45.5)		13 (39.4)	20 (60.6)
Tumor location
Head, neck	56	23 (41.1)	33 (58.9)	0.278a	26 (46.4)	30 (53.6)	0.757a
Body, tail	28	15 (53.6)	13 (46.4)		12 (42.9)	16 (57.1)
Tumor size (cm)
≤ 3	25	10 (40.0)	15 (60.0)	0.530a	12 (48.0)	13 (52.0)	0.741a
> 3	59	28 (47.5)	31 (52.5)		26 (44.1)	33 (55.9)
Tumor differentiation
Well, moderate	57	27 (47.4)	30 (52.6)	0.569a	26 (45.6)	31 (54.4)	0.920a
Poor	27	11 (40.7)	16 (59.3)		12 (44.4)	15 (55.6)
Invasion depth
T1 + T2	71	35 (49.3)	36 (50.7)	0.081a	29 (40.8)	42 (59.2)	0.059a
T3 + T4	13	3 (23.1)	10 (76.9)		9 (69.2)	4 (30.8)
Lymph nodes metastasis
N0 (negative)	51	32 (62.7)	19 (37.3)	< 0.001a*	23 (45.1)	28 (54.9)	0.974a
N1 (positive)	33	6 (18.2)	27 (81.8)		15 (45.5)	18 (54.5)
Distant metastasis
Absent	82	38 (46.3)	44 (53.7)	0.499b	36 (43.9)	46 (56.1)	0.202b
Present	2	0 (0)	2 (100)		2 (100)	0 (0)
Clinical stage
Early stages (≤ IIa)	49	31 (63.3)	18 (36.7)	< 0.001a*	22 (44.9)	27 (55.1)	0.941a
Advanced stages (> IIa)	35	7 (20.0)	28 (80.0)		16 (45.7)	19 (54.3)
Abdominal pain
Absent	38	16 (42.1)	22 (57.9)	0.600a	19 (50.0)	19 (50.0)	0.425a
Present	46	22 (47.8)	24 (52.2)		19 (41.3)	27 (58.7)
Jaundice
Absent	69	33 (47.8)	36 (52.2)	0.307a	31 (44.9)	38 (55.1)	0.902a
Present	15	5 (33.3)	10 (66.7)		7 (46.7)	8 (53.3)
Nervous invasion
Negative	51	19 (37.3)	32 (62.7)	0.068a	26 (51.0)	25 (49.0)	0.189a
Positive	33	19 (57.6)	14 (42.4)		12 (36.4)	21 (63.6)

^aChi-square test.

^bFisher's exact test.

^*P < 0.05 indicates a significant association among the variables.